Barclays Cuts Definitive Healthcare (NASDAQ:DH) Price Target to $3.00

Definitive Healthcare (NASDAQ:DH) had its price target reduced by Barclays from $4.00 to $3.00 in a research report sent to investors on Monday morning,Benzinga reports. Barclays currently has an underweight rating on the stock.

A number of other research firms have also issued reports on DH. Needham & Company LLC restated a “hold” rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. Stephens assumed coverage on Definitive Healthcare in a research report on Friday, December 20th. They set an “equal weight” rating and a $5.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Definitive Healthcare presently has an average rating of “Hold” and a consensus price target of $5.35.

Definitive Healthcare Price Performance

Shares of DH opened at $2.77 on Monday. The firm has a market cap of $320.00 million, a price-to-earnings ratio of -0.89, a PEG ratio of 4.06 and a beta of 1.45. The stock has a 50 day moving average of $4.55 and a 200-day moving average of $4.45. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.33. Definitive Healthcare has a 52 week low of $2.58 and a 52 week high of $8.71.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.04). The firm had revenue of $62.29 million during the quarter, compared to analyst estimates of $60.60 million. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. As a group, analysts forecast that Definitive Healthcare will post 0.16 EPS for the current year.

Institutional Trading of Definitive Healthcare

Hedge funds have recently added to or reduced their stakes in the business. Irenic Capital Management LP raised its stake in shares of Definitive Healthcare by 9.2% in the 4th quarter. Irenic Capital Management LP now owns 7,003,194 shares of the company’s stock worth $28,783,000 after buying an additional 590,009 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Definitive Healthcare by 36.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 6,053,233 shares of the company’s stock worth $27,058,000 after buying an additional 1,626,813 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Definitive Healthcare by 1.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,863,912 shares of the company’s stock worth $7,661,000 after buying an additional 23,410 shares in the last quarter. State Street Corp raised its stake in shares of Definitive Healthcare by 29.4% in the 3rd quarter. State Street Corp now owns 1,399,729 shares of the company’s stock worth $6,257,000 after buying an additional 317,952 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Definitive Healthcare by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 1,272,660 shares of the company’s stock worth $5,231,000 after buying an additional 39,938 shares in the last quarter. Institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.